Trial Profile
A phase 3 trial to evaluate the safety and efficacy of the specific immunotherapy, recombinant idiotype conjugated to KLH [keyhole limpet haemocyanin] (GTOP 99) with GM-CSF [granulocyte-macrophage colony-stimulating factors], compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2008
Price :
$35
*
At a glance
- Drugs GTOP 99 (Primary)
- Indications B-cell lymphoma; Follicular lymphoma
- Focus Registrational; Therapeutic Use
- 09 May 2008 Status change
- 16 Apr 2008 Status change from in progress to completed
- 16 Apr 2008 Results presented at AACR in 2008